You are here

Allergan

Court Finds Restasis Patents Invalid, Raises Concerns About Allergan, Mohawk Tribe Agreement

Court Finds Restasis Patents Invalid, Raises Concerns About Allergan, Mohawk Tribe Agreement

RAPS.org

Flag link:

'Sham' or legit? Texas judge set to weigh in on Allergan's tribal patent deal

'Sham' or legit? Texas judge set to weigh in on Allergan's tribal patent deal

Fierce Pharma

Flag link:

Allergan settles Restasis patent challenge after moving patents to Native American tribe

Allergan settles Restasis patent challenge after moving patents to Native American tribe

Drug Delivery Business News

Flag link:

Ten big lobbying groups turn their guns on Allergan’s controversial patent gambit

Ten big lobbying groups turn their guns on Allergan’s controversial patent gambit

Endpoints

Flag link:

Allergan's Forest Labs to pay $4 million to settle discrimination charges by former sales reps

Allergan's Forest Labs to pay $4 million to settle discrimination charges by former sales reps

Reuters

gender discrimination

Flag link:

Allergan shows how you can destroy your rep and get mobbed by lawmakers in 4 easy steps

Allergan shows how you can destroy your rep and get mobbed by lawmakers in 4 easy steps

Endpoints

Flag link:

3 Big Pharma Stocks Set to Succeed

3 Big Pharma Stocks Set to Succeed

Motley Fool

Flag link:

Allergan moneymaker Botox grabs another cosmetic approval, this time in forehead lines

Allergan moneymaker Botox grabs another cosmetic approval, this time in forehead lines

Fierce Pharma

Flag link:

Allergan defends Restasis deal by calling for review of patent challenge process

Allergan defends Restasis deal by calling for review of patent challenge process

Fierce Pharma

Flag link:

Allergan’s tribal treaty in Restasis patent fight triggers a Congressional dispute

Allergan’s tribal treaty in Restasis patent fight triggers a Congressional dispute

Endpoints

Flag link:

Allergan: $2 Billion Share Buybacks Confirm Growth Is Dead

Allergan: $2 Billion Share Buybacks Confirm Growth Is Dead

Seeking Alpha

share repurchase

Flag link:

Allergan hit with FDA refusal to file letter

Allergan hit with FDA refusal to file letter

BioPharma Dive

refuse to file letters

Flag link:

Two years on, Allergan’s $1.7B NASH drug still looks weak — at best

Two years on, Allergan’s $1.7B NASH drug still looks weak — at best

Endpoints

Flag link:

Apple Likes the Patent ‘Death Squad.’ Allergan Pays to Avoid It

Apple Likes the Patent ‘Death Squad.’ Allergan Pays to Avoid It

Bloomberg

Flag link:

States Push Ahead With Investigation Into Opioid Painkillers

States Push Ahead With Investigation Into Opioid Painkillers

FOX Business

Endo International

Teva Pharmaceutical

Flag link:

This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge

This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge

Stat

Flag link:

FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche’s Avastin

FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche’s Avastin

Endpoints

Flag link:

Mylan attacks Allergan over its Mohawk-allied patent strategy — but the CEO is sticking to his guns

Mylan attacks Allergan over its Mohawk-allied patent strategy — but the CEO is sticking to his guns

Endpoints

Flag link:

Allergan's Patent Loophole Could Be a Huge Gift for Pfizer

Allergan's Patent Loophole Could Be a Huge Gift for Pfizer

Motley Fool

Flag link:

Allergan CEO gambles a multibillion-dollar franchise — and his company rep — on a high-stakes bet at an Indian casino op

Allergan CEO gambles a multibillion-dollar franchise — and his company rep — on a high-stakes bet at an Indian casino op

Endpoints

Flag link: